Stock Analysis Report

Executive Summary

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States.

Snowflake Analysis

Imperfect balance sheet with weak fundamentals.

Similar Companies

Share Price & News

How has Curis's share price performed over time and what events caused price changes?

Latest Share Price and Events

Stable Share Price: CUSA's share price has been volatile over the past 3 months.

Market Performance

7 Day Return




DE Biotechs


DE Market

1 Year Return




DE Biotechs


DE Market

Return vs Industry: CUSA exceeded the German Biotechs industry which returned 7.2% over the past year.

Return vs Market: CUSA exceeded the German Market which returned 14.1% over the past year.

Shareholder returns

7 Day0%0.4%0.2%
30 Day-11.3%-2.1%0.9%
90 Day-8.3%8.0%4.6%
1 Year37.1%37.1%9.2%9.0%17.9%14.4%
3 Year-88.7%-88.7%45.5%43.9%15.7%5.6%
5 Year-90.3%-90.3%12.8%10.5%23.4%6.5%

Price Volatility Vs. Market

How volatile is Curis's share price compared to the market and industry in the last 5 years?

Simply Wall St News

No news available


Is Curis undervalued compared to its fair value and its price relative to the market?

In this section, we usually try to help investors determine whether Curis is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Curis has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.

Next Steps

Future Growth

How is Curis forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?


Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Curis has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Next Steps

Past Performance

How has Curis performed over the past 5 years?


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: CUSA is currently unprofitable.

Growing Profit Margin: CUSA is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: CUSA is unprofitable, but has reduced losses over the past 5 years at a rate of 1.2% per year.

Accelerating Growth: Unable to compare CUSA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CUSA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).

Return on Equity

High ROE: CUSA's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.

Return on Assets

Return on Capital Employed

Next Steps

Financial Health

How is Curis's financial position?

Financial Position Analysis

Short Term Liabilities: CUSA has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: CUSA has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.

Debt to Equity History and Analysis

Debt Level: CUSA is debt free.

Reducing Debt: CUSA's has negative shareholder equity, so we do not need to check if its debt has reduced over time.

Balance Sheet

Inventory Level: CUSA has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if CUSA's debt is covered by short term assets.

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CUSA has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: CUSA has less than a year of cash runway if free cash flow continues to reduce at historical rates of -14.1% each year

Next Steps


What is Curis's current dividend yield, its reliability and sustainability?

Dividend Yield vs Market

Notable Dividend: Unable to evaluate CUSA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate CUSA's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CUSA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CUSA's dividend payments have been increasing.

Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CUSA's dividend in 3 years as they are not forecast to pay a notable one for the German market.

Next Steps


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Jim Dentzer (52yo)





Mr. James E. Dentzer, also known as Jim, has been President, Chief Executive Officer, Secretary and Director at Curis, Inc since September 24, 2018 and was its Treasurer since September 24, 2018. Mr. Dentz ...

CEO Compensation Analysis

Compensation vs Market: Jim's total compensation ($USD1.96M) is above average for companies of similar size in the German market ($USD413.42K).

Compensation vs Earnings: Jim's compensation has increased whilst the company is unprofitable.

Leadership Team

James Dentzer
President1.4yrsUS$1.96m0.13% $56.3k
Robert Martell
Head of Research & Development1.7yrsUS$1.20m0.069% $30.7k
William Steinkrauss
Chief Financial Officer0yrsno data0.029% $13.0k
Mark Noel
Vice President of Technology Management & Intellectual Property11.4yrsUS$413.39kno data
Reinhard von Roemeling
Senior Vice President of Clinical Development0.5yrsno datano data
Daniel Passeri
Consultant3.4yrsUS$552.80kno data


Average Tenure


Average Age

Experienced Management: CUSA's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.

Board Members

James Dentzer
President1.4yrsUS$1.96m0.13% $56.3k
Martyn Greenacre
Independent Chairman of the Board0yrsUS$234.87k0.079% $34.8k
Marc Rubin
Independent Director9.7yrsUS$207.65k0.087% $38.5k
Kenneth Kaitin
Independent Director16.3yrsUS$200.15k0.085% $37.5k
Lori Kunkel
Independent Director3.3yrsUS$179.13k0.067% $29.6k


Average Tenure


Average Age

Experienced Board: CUSA's board of directors are considered experienced (6.5 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: CUSA insiders have only sold shares in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Company Information

Curis, Inc.'s company bio, employee growth, exchange listings and data sources

Key Information

  • Name: Curis, Inc.
  • Ticker: CUSA
  • Exchange: DB
  • Founded: 2000
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$47.812m
  • Listing Market Cap: US$44.303m
  • Shares outstanding: 33.20m
  • Website: https://www.curis.com

Number of Employees


  • Curis, Inc.
  • 4 Maguire Road
  • Lexington
  • Massachusetts
  • 2421
  • United States


TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CRISNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDAug 2000
CUSADB (Deutsche Boerse AG)YesCommon StockDEEURAug 2000


Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CUDC-907, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors; CA-170, an oral small molecule drug candidate for treating patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas; and CA-327, a pre-investigational new drug stage oncology drug candidate. The company has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; and with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. The company also has a scientific collaboration with DarwinHealth, Inc. to characterize biomarkers and tumor subtype alignments for Fimepinostat in DLBCL and solid malignancies. Curis, Inc. was founded in 2000 and is headquartered in Lexington, Massachusetts. 

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/20 20:45
End of Day Share Price2020/02/20 00:00
Annual Earnings2018/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.